1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: ASCO preview; Asahi Kasei’s US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 31 May 2024, including: ASCO preview; Asahi Kasei Corporation’s US acquisition; Novartis AG aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "ASCO Preview: Five Presentations To Watch Out For" - Scrip, 23 May, 2024.)

(Also see "Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy" - Scrip, 28 May, 2024.)

(Also see "Novartis Aims To Dominate Rare Renal Disorders" - Scrip, 25 May, 2024.)

(Also see "Could Combining Strategies Be A Way Forward To Pay For Gene Therapies?" - Scrip, 28 May, 2024.)

(Also see "BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD" - Scrip, 24 May, 2024.)

Citeline · Scrip's Five Must-Know Things - 3 June 2024

Open Media

More from Clinical Trials

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 
• By Dexter Jie Yan

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss

 
• By Alaric DeArment

The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.

Almirall CEO Sounds Alarm Over Europe’s Reduced Competitiveness

 
• By Kevin Grogan

The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

More from R&D

Stock Buyback Is Vote Of Confidence From Genmab Board

 
• By Kevin Grogan

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 
• By Alexandra Shimmings

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By Kevin Grogan

A decision from the FDA is due by 28 September.